Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24162954 | 0.97 | HPGD (0.68) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24162961 | 0.85 | NPC1 (0.59) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24162901 | 0.84 | NPC1 (0.56) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL25414340 | 0.81 | OXTR (0.56) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL16496157 | 0.80 | RAB9A (0.67) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24163871 | 0.79 | NPC1 (0.59) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL1675462 | 0.78 | NPC1 (0.63) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24163870 | 0.78 | NPC1 (0.57) | HPGDRAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL24162948 | 0.78 | RAB9A (0.57) | RAB9ANPC1KMT2AHSP90AA1LMNA | |
| SCHEMBL5835725 | 0.77 | HPSE (0.62) | HPGDRAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | claimed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| WO-2022006534-A1 | TARGETING SERPIN B9 IN CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | HPGD 1255/4885RAB9A 338/4885NPC1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.